Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Patients have given written informed consent
Body mass index (BMI) ≥ 25 to ≤ 50 kg/m²
For patients with type 2 diabetes mellitus: either naive of glucose lowering drug or under stable oral glucose lowering drug
Estimated glomerular filtration rate (eGFR) ≥ 60 mL/\[min\*1.73m²\]
Alanine amino transferase (ALT) \> 20 IU/L in females and \> 30 IU/L in males
Hepatic steatosis (MRI-PDFF ≥ 10%)
Effective contraception for women of child bearing potential

Evidence of another form of liver disease
Evidence of liver cirrhosis
Evidence of hepatic impairment
Positive serologic evidence of current infectious liver disease
History of excessive alcohol intake
Acute cardiovascular disease with 24 weeks prior to screening
Uncontrolled high blood pressure
Any disease which in the Investigator's opinion which in the Investigator's opinion would exclude the patient from the study
Use of non-permitted concomitant medication
Pregnancy or lactation

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD